AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 1/2Trial registry
Safety and Tolerability of TRX319 in Human Subjects with Progressive Multiple Sclerosis
A Phase 1/2 study was conducted to evaluate the safety and tolerability of TRX319 infusion in human subjects with Primary or Secondary Progressive Multiple Sclerosis. No results are publicly available yet, and the study was non-randomized.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
Understanding the safety of TRX319 is crucial as it may lead to new treatment options for those with progressive forms of MS, which currently have limited therapies.
What this does not prove
The lack of posted results means we cannot assess the effectiveness or concrete safety profile of TRX319; planned enrollment and endpoints do not provide findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (10)
study phase"officialTitle": "A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis",
subjects"measure": "To assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.",
randomized"allocation": "NON_RANDOMIZED",
regulatory approval"isFdaRegulatedDrug": true
regulatory approval details"isFdaRegulatedDrug": true
intervention"Biological: TRX319",
primary endpointTo assess the safety and tolerability of TRX319 infusion in subjects with Primary Progressive or Secondary Progressive Multiple Sclerosis.
follow upFrom baseline until 12 months post TRX319 Infusion
findingsNo results are posted.
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.